Drug Profile


Alternative Names: UK 81252

Latest Information Update: 28 May 2003

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 19 May 2003 No development reported - Phase-II for Congestive heart failure in United Kingdom (unspecified route)
  • 19 May 2003 No development reported - Phase-II for Hypertension in United Kingdom (unspecified route)
  • 27 Dec 2000 Phase-II clinical trials in Hypertension in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top